Ignite Creation Date:
2024-05-06 @ 5:30 PM
Last Modification Date:
2024-10-26 @ 2:30 PM
Study NCT ID:
NCT05335473
Status:
RECRUITING
Last Update Posted:
2023-04-06
First Post:
2022-04-13
Brief Title:
Iribrine Plus Tucidinostat in the Treatment of HRHER2 Advanced Breast Cancer After CDK46 Inhibitor Failure
Sponsor:
Henan Cancer Hospital
Organization:
Henan Cancer Hospital
Organization Data
Organization:
Henan Cancer Hospital
Class:
OTHER_GOV
Study ID:
HNCH-MBC07
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Henan Cancer Hospital
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Min Yan MD
Responsible Party Title:
Chief Physician
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Henan Cancer Hospital
Old Name:
None
Old Organization:
None